Anova is managing the delivery of Phase 1/2a study of DB107 at UCSF, USC, UCSD and with Denovo Biopharma DB107 is a proprietary gene therapy platform for the treatment of patients with newly diagnosed ...

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, has ...

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San ...

Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...

Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...